Clinical efficacy and safety of apatinib in treatment of alpha fetoprotein-positive advanced gastric cancer
XUN Chen
WANG Lin
ZHANG Yu
HUANG Wei
QIN Shukui
Abstract：Objective To evaluate the efficacy and safety of apatinib in advanced alpha fetoprotein (AFP)-positive gastric cancer.Methods Seven patients with advanced AFP-positive gastric cancer from September 2009 to January 2017 received apatinib were enrolled.All the patients were given apatinib alone or in combination with chemotherapy,and the dose of apatinib was 250-850 mg/d.The efficacy and safety were evaluated by RECIST criteria (version 1.1) and NCI CTC 4.0 criteria.Overall survival (OS) and progression-free survival (PFS) were analyzed by Kaplan-Meier method.Results All patients were available for evaluation.Among the 7 patients,1 case got partial respond and 3 cases had stable disease.The response rate was 14.3％ and disease control rate was 57.1％.The median PFS was 4.0 months (95％CI:0-9.1) and the median OS was 7.0 months (95％CI:5.7-8.3).Among the 7 patients,the APF level decreased in 5 cases.The common treatment-related side effects included hypertension,proteinuria,thrombocytopenia and neutropenia,mainly in grade 1-3.Except one patient discontinued apatinib treatment due to grade 3 hypertension,the side effects were controlled and tolerated well in the other patients.Conclusion Apatinib is effective and tolerable in advanced AFP-positive gastric cancer.
Keywords：Gastric cancerAlpha fetoprotein (AFP)Apatinib
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 924-928 )